Varian offers new planning tool as stock slides
The bad news continued as Varian Medical Systems lost a major supply contract to rival Elekta in late July. Earlier in the month, the company reported preliminary results that showed sales of radiotherapy equipment were flat in the U.S. last quarter,
The bad news continued as Varian Medical Systems lost a major supply contract to rival Elekta in late July. Earlier in the month, the company reported preliminary results that showed sales of radiotherapy equipment were flat in the U.S. last quarter, sending its stock spiraling downward (SCAN 7/16/04).
News that Elekta had won a key three-year contract to supply Premier Purchasing Partners with radiation oncology systems knocked the company's stock down even further. Fearful of more bad news, investors sent the stock plummeting to hover just above the $60 mark in anticipation of final quarterly results after the market close July 29. The stock had cracked the $90 level in April.
On the up side, Varian introduced several new capabilities in July for its Eclipse 3D radiotherapy treatment planning software. The new software compensates automatically for variations in tissue thickness and has the ability to combine multiple targets within a single plan. Another enhancement supports inverse planning of IMRT treatments with linear accelerators from other suppliers.
ASCO: Study Reveals Significant Racial/Ethnic Disparities with PSMA PET Use for Patients with mPCa
May 30th 2025Latinx patients with metastatic prostate cancer were 63 percent less likely than non-Hispanic White patients to have PSMA PET scans, according to a study of 550 patients presented at the American Society of Clinical Oncology (ASCO) conference.
Lunit Unveils Enhanced AI-Powered CXR Software Update
May 28th 2025The Lunit Insight CXR4 update reportedly offers new features such as current-prior comparison of chest X-rays (CXRs), acute bone fracture detection and a 99.5 percent negative predictive value (NPV) for identifying normal CXRs.
New MRI Study Questions Use of Corticosteroid Injections for Knee OA
May 27th 2025Two years after intraarticular knee injections for knee osteoarthritis (OA), study participants who had corticosteroid knee injections had greater OA progression than control patients while the use of hyaluronic acid injections was associated with less OA progression.
